Incidence of infections caused by carbapenem-resistant Acinetobacter baumannii

被引:21
|
作者
Rossi, Iara [1 ]
Royer, Sabrina [1 ]
Ferreira, Melina Lorraine [1 ]
Campos, Paola Amaral [1 ]
Fuga, Bruna [1 ]
Melo, Gabriel Nogueira [1 ]
Machado, Luiz Gustavo [1 ]
Resende, Daiane Silva [1 ]
Batistao, Deivid [1 ,2 ]
Urzedo, Jane Eire [3 ]
Gontijo-Filho, Paulo P. [1 ]
Ribas, Rosineide Marques [1 ,3 ]
机构
[1] Univ Fed Uberlandia, Biomed Sci Inst, Lab Mol Microbiol, 1720 Para Ave, BR-38400000 Uberlandia, MG, Brazil
[2] Univ Fed Uberlandia, Sch Med, Uberlandia, MG, Brazil
[3] Univ Fed Uberlandia, Hosp Clin, Hosp Infect Control Comm, Uberlandia, MG, Brazil
关键词
Carbapenem-resistance; Outbreak; KLEBSIELLA-PNEUMONIAE; TRANSMISSION; OUTBREAK; SURVEILLANCE; EMERGENCE; MORTALITY; EVOLUTION; RISK;
D O I
10.1016/j.ajic.2019.07.009
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Carbapenem-resistant Acinetobacter baumannii (CR-Ab) has become a worrying health care problem, mainly in developing countries, such as Brazil. The objective was to investigate the prevalence and prognostic factors for CR-Ab infections at a Brazilian university hospital and examine the impact of inappropriate antimicrobial therapy on patient outcome. Methods: A retrospective study on hospitalized patientswith CR-Ab infectionswas carried out from January 2013 to December 2017. An epidemiologic analysis was carried out to determine the frequency of infections, the epidemiologic indicators by year, the risk factors for 30-day mortality, and the impact of inappropriate therapy. Results: A total of 489 patients were included in the study. A rate of 0.7 per 1,000 patient-day CR-Ab infections was observed, mostly in the lungs (54.7%), and predominantly in the adult intensive care unit. The occurrence of infections by CR-Ab per 1,000 patient-days in November 2014 exceeded the established control limit, confirming an outbreak. Conclusions: The prevalence of CR-Ab increased in the investigated hospital, passing to an endemic pathogen with a direct impact on mortality and the control of these strains. (C) 2019 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:1431 / 1435
页数:5
相关论文
共 50 条
  • [21] Analysis of risk factors and different treatments for infections caused by carbapenem-resistant Acinetobacter baumannii in Shaanxi, China
    He, Xiaoliang
    Tang, Jin
    He, Sanjun
    Huang, Xiaoxia
    BMC INFECTIOUS DISEASES, 2024, 24 (01)
  • [22] Associations between Carbapenem Use, Carbapenem-Resistant Pseudomonas aeruginosa, and Carbapenem-Resistant Acinetobacter baumannii
    Apisarnthanarak, Anucha
    Jitpokasem, Sumana
    Mundy, Linda M.
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2013, 34 (11): : 1235 - 1237
  • [23] Treatment Options for Carbapenem-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections
    Viehman, J. Alexander
    Hong Nguyen, M.
    Doi, Yohei
    DRUGS, 2014, 74 (12) : 1315 - 1333
  • [24] Rare purulent pericarditis caused by carbapenem-resistant Acinetobacter baumannii A case report
    Liu, Jingjing
    Xiao, Xuefei
    Cen, Chaoqun
    Yuan, Hong
    Yang, Mingshi
    MEDICINE, 2019, 98 (38)
  • [25] Sulbactam and Durlobactam Combination as a Newer Antibiotic for Carbapenem-Resistant Acinetobacter baumannii Infections
    Nyamagoud, Sanatkumar Bharamu
    Swamy, Agadi Hiremath Viswanatha
    Abhishek, B. J.
    Varghese, Leena Elizabeth
    Bhoomika, S. K.
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL INVESTIGATION, 2024, 14 (02) : 289 - 298
  • [26] Hemorrhagic bronchitis caused by carbapenem-resistant Acinetobacter baumannii infection: A case report
    Li, Zifang
    Sheng, Yu
    Huang, Dongdong
    RESPIRATORY MEDICINE CASE REPORTS, 2024, 48
  • [27] Intravenous Fosfomycin: The Underdog Player in the Treatment of Carbapenem-resistant Acinetobacter baumannii Infections
    Guastalegname, Maurizio
    Trecarichi, Enrico Maria
    Russo, Alessandro
    CLINICAL INFECTIOUS DISEASES, 2023, 77 (12) : 1736 - 1737
  • [28] Clinical characterization of patients with carbapenem-resistant versus carbapenemsusceptible Acinetobacter baumannii infections
    Tyagi, I.
    Koirala, J.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2010, 14 : E44 - E44
  • [29] Endemic carbapenem-resistant Acinetobacter baumannii in a London hospital
    Manuel, RJ
    Shin, GY
    Farrag, N
    Holliman, R
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (01) : 141 - 142
  • [30] Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment
    Piperaki, E. -T.
    Tzouvelekis, L. S.
    Miriagou, V.
    Daikos, G. L.
    CLINICAL MICROBIOLOGY AND INFECTION, 2019, 25 (08) : 951 - 957